Abstract: Pelabresib (CPI-0610) is a novel, first-in-class small molecule inhibitor targeting the bromodomain and extra-terminal domain (BET) family of proteins. While current standard-of-care therapies for myeloproliferative neoplasms (MPNs), such as Janus kinase (JAK) inhibitors, effectively manage symptom burden and splenomegaly, they fail to prevent disease progression or transformation into acute myeloid leukemia (AML). Pelabresib addresses this unmet clinical need by acting as a disease-modifying agent. By inhibiting BRD4, pelabresib downregulates the transcription of key oncogenes like MYC and attenuates the pro-inflammatory NF-κB signaling pathway, which are critical drivers in the pathogenesis of both myelofibrosis and AML. Clinical data from the MANIFEST trials demonstrate that pelabresib, both as a monotherapy and in combination with ruxolitinib, significantly improves spleen volume, symptom burden, and bone marrow fibrosis. This review synthesizes the current literature on pelabresib, detailing its pharmacological activity, molecular mechanisms, structural interactions, clinical limitations, and future perspectives in the context of preventing and treating advanced hematological malignancies.
1. Introduction
Myelofibrosis (MF) is a severe myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, splenomegaly, and a high propensity for leukemic transformation into acute myeloid leukemia (AML) [1][5]. The current cornerstone of therapy for these patients relies on Janus kinase (JAK) inhibitors, such as ruxolitinib and fedratinib. While these agents provide undeniable benefits in reducing spleen size and constitutional symptoms, they possess limited "disease-modifying" capabilities. Specifically, JAK inhibitors do not significantly reduce mutant allele burdens, reverse bone marrow fibrosis, or prevent the eventual disease evolution to AML [3][7]. Furthermore, patients who become refractory to or intolerant of JAK inhibitors face a dismal prognosis and a higher risk of leukemic transformation [1].
To overcome these limitations, therapeutic development has shifted toward targets outside the JAK-STAT pathway, focusing on epigenetic modulation to deplete malignant stem cells. Pelabresib (CPI-0610) has emerged as a highly promising epigenetic therapeutic. As a potent inhibitor of the bromodomain and extra-terminal (BET) proteins, pelabresib is currently being investigated for its ability to alter the natural history of MPNs, improve cytopenias, and potentially halt the progression to acute leukemia [1][3].
2. Pharmacological Activity
Pelabresib has demonstrated robust pharmacological activity in multiple clinical settings, primarily evaluated through the comprehensive Phase 2 MANIFEST study. The drug has been tested across different patient cohorts: as a monotherapy in JAK-inhibitor refractory/intolerant patients, as an "add-on" therapy for patients with suboptimal responses to ruxolitinib, and as an upfront combination therapy with ruxolitinib in JAK-inhibitor-naive patients [1].
In the monotherapy cohort for patients refractory to JAK inhibitors, pelabresib showed notable efficacy in ameliorating anemia. Among transfusion-dependent patients, 21.4% to 23.8% converted to transfusion independence, and up to 24% of evaluable patients achieved a ≥35% spleen volume reduction (SVR35) at 24 weeks [1][3]. When utilized as an add-on therapy to ruxolitinib, 34.4% of transfusion-dependent patients achieved independence, with 20.8% achieving SVR35 and 46.2% achieving a ≥50% reduction in total symptom score (TSS50) [1].
The most striking pharmacological activity was observed in the upfront combination setting. In JAK-inhibitor-naive patients, the combination of pelabresib and ruxolitinib resulted in an SVR35 of 66% to 68% and a TSS50 of 53% to 56% [2]. Importantly, this combination exhibited disease-modifying effects, with 28% to 33% of patients showing at least a 1-grade improvement in bone marrow fibrosis and significant reductions in the JAK2V617F mutant allele fraction [1][5]. Pharmacokinetic analyses indicate that pelabresib is orally bioavailable with a terminal elimination half-life (T1/2) of approximately 16 hours [4].
3. Molecular Mechanism of Action
The molecular mechanism of pelabresib centers on the inhibition of the BET family of epigenetic reader proteins, which includes BRD2, BRD3, BRD4, and BRDt [1][4]. Under normal physiological conditions, BET proteins recognize and bind to acetylated lysine residues on histone tails. This binding facilitates the recruitment of regulatory complexes, such as positive transcription elongation factor b (P-TEFb), which drive the transcription of various genes [1][4].
Pelabresib specifically targets and inhibits BRD4. This inhibition has two major downstream effects critical to the treatment of MPNs and the prevention of AML. First, BRD4 inhibition attenuates the NF-κB signaling pathway. Because NF-κB plays a pivotal role in the pro-inflammatory state that characterizes myelofibrosis, its suppression dampens the inflammatory response of bone marrow-derived macrophages, significantly reducing the expression of cytokines such as IL-6, IFN-β1, IL-1β, IL-12a, CXCL9, and CCL12 [1][3]. Second, BET inhibition downregulates the transcription of key oncogenes, most notably MYC. The overexpression of MYC is heavily implicated in the tumorigenesis and progression of multiple malignancies, including acute myeloid leukemia [4]. By modulating these transcriptional networks, pelabresib also modifies megakaryocyte differentiation and proliferation, directly addressing the root cause of bone marrow fibrosis [5].
4. Structure-Activity Relationship (SAR)
While exhaustive chemical structure-activity relationship data is not fully detailed in the provided clinical literature, the fundamental interaction of pelabresib relies on its ability to competitively bind to the BRD-acetyl binding pocket of BET proteins [4]. By occupying this specific pocket, the small molecule physically blocks the BET proteins from docking onto acetylated histones at super-enhancers and promoter regions of the chromatin [4]. The clinical efficacy of BET inhibitors like pelabresib is heavily dependent on their binding affinity and selectivity for the bromodomains (BD1 or BD2). This targeted blockade is what selectively downregulates the transcription of oncogenes like MYC and inflammatory drivers like NF-κB without completely abolishing global gene transcription [4].
5. Current Limitations
Despite its promising efficacy, the clinical application of pelabresib is constrained by its adverse event (AE) profile. The most common and severe toxicities associated with BET inhibitors are hematological. Exposure-dependent thrombocytopenia is a primary dose-limiting toxicity, observed frequently in clinical trials alongside anemia and neutropenia [1][4]. In the MANIFEST study, grade 3 or 4 thrombocytopenia and anemia were notable treatment-emergent adverse events (TEAEs) that required careful clinical management [1].
Non-hematological adverse events also pose a limitation to patient tolerability. The most frequently reported non-hematological AEs include gastrointestinal disturbances such as nausea and diarrhea, as well as fatigue, dysgeusia (altered taste), and decreased appetite [4]. Furthermore, severe (grade 3 or 4) non-hematological AEs such as pneumonia and elevated bilirubin have been documented with the broader class of BET inhibitors [4]. These toxicities necessitate rigorous dose optimization and monitoring to balance anti-leukemic efficacy with patient safety.
6. Future Perspectives
The future development of pelabresib is highly focused on combination strategies that can synergize with existing therapies to alter the disease course of MPNs and prevent transformation to AML. The ongoing global, randomized, double-blind Phase 3 MANIFEST-2 trial (NCT04603495) is currently evaluating the combination of pelabresib and ruxolitinib versus ruxolitinib plus placebo in JAK-inhibitor-naive patients [1][2][7]. Interim data suggest that this combination is well-tolerated and yields superior clinical outcomes across all risk groups [5].
If Phase 3 trials confirm the disease-modifying effects seen in earlier phases—such as the reversal of bone marrow fibrosis and the reduction of mutant allele burdens—pelabresib could facilitate a paradigm shift in hematological oncology [3][5]. Moving forward, exploring the efficacy of pelabresib in direct AML models, given its potent MYC-downregulating capabilities, represents a critical next step. The integration of BET inhibitors early in the disease course may ultimately prevent the genetic evolution and leukemic transformation that currently limits the survival of patients with myeloproliferative neoplasms [6].
